Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.
Qiao-Juan Guo, Qin Liu, Paolo Bossi et al.
✦ AI-curated · Sources linked
In 30 seconds
This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent. Fifty-four experts from 46 centres in 18 countries or regions developed 32 recommendations across seven clinical domains; 29 were strong and three conditional. The guideline recommends offering curative-intent treatment to medically fit patients with no more than three metastatic lesions in two or fewer organs, either at baseline or after response to systemic therapy. Recommended multimodality care includes immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy.
Key findings
- The guideline contains 32 recommendations across seven clinical domains: 29 strong and three conditional.
- Curative-intent treatment is recommended for medically fit patients with no more than three metastatic lesions in two or fewer organs, at baseline or after systemic therapy response.
- Recommended multimodality treatment comprises immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy.
Why it matters
The guideline provides a structured approach to selecting patients with de novo metastatic nasopharyngeal carcinoma for curative-intent management, rather than assuming treatment must be palliative. Its recommendations also clarify the proposed combination of systemic and local therapies and identify evidence gaps that require future research.
What to keep in mind
This is a consensus guideline, not a trial establishing treatment effects; the abstract does not report comparative outcome data supporting the recommendations.